Wed, Oct 1, 2014, 6:43 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Athenahealth, Inc. (ATHN) Message Board

mghmd 4 posts  |  Last Activity: Sep 2, 2014 11:41 PM Member since: Jan 22, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • CPXX selected the ph2 group of AML patients with the most impressive response to its drug- patients with secondary or very high risk AML for its ph3 study. Ph3 of the drug nearing completion with full backing of Leukemia and Lymphoma Society and a market cap for CPXX only a fraction of that of SNSS. I think it has a much better chance for a clinically significant ph3 outcome and big upside potential. I am strongly long CPXX. Take a look at the company website and listen to the last presentation.

  • Reply to

    This Stinks! Vote NO! File a lawsuit!

    by sjohns544 Aug 10, 2014 11:04 PM
    mghmd mghmd Aug 11, 2014 5:07 PM Flag

    I am in the same situation. I will vote NO unless there is a much larger premium.

  • mghmd by mghmd Jul 24, 2014 8:57 AM Flag

    Dr. Sharman's CLL & NHL Blog
    Idelalisib / Zydelig approved
    Posted: 23 Jul 2014 09:37 AM PDT
    There is a new kid on the block!

    First it was called CAL-101. It is common for a drug company to use letters from the name of the company. In this case, it was originally Calistoga Pharmaceuticals. The 101 part is a little more funny. I understand one of the early investors in the company was driving in Palo Alto California and turned from University Drive onto the 101 highway and decided to call the drug CAL-101. True? False? Not sure.

    Then Gilead bought up the drug from Calistoga. Next step? Change the numbers. CAL-101 became GS-1101. GS = Gilead Science. Not sure where the extra "1" came from. Perhaps it was an effort to differentiate from GA-101 which became obinutuzumab before it became Gazyva.

    Next step is to give the letter / number combo an actual name. In this case it was idelalisib. As difficult as that seems, it actually makes perfect sense.

    Idelalisib (pronounced I-Dela-Lisib)
    I=inhibit
    Dela= delta isoform of PI3K
    Lisib = that is the mandatory suffix of drugs that inhibit PI3K enzymes

    I have heard this drug mispronounced so many ways that it is almost comical -I-del-isilib, I-dela-mab, etc. I think I would have chosen Ideltalisib if I were in control of all things as that would make a lot of sense (inhibit-delta-PI3K).

    Every drug has two names (brand name vs generic name). You would be amazed how much effort goes into coming up with a name for a drug. You would also be amazed how often drug names begin with the letter "Z." Some sort of market research I don't know about I suppose. So idelalisib is now called Zydelig. I think this is a combo of the "z" and the "delta" but not sure I know where the "ig" comes from.

    As if we were not already spoiled by approvals of the latest treatments for CLL including the addition of obinutuzumab and ibrutinib within the last 12 months, now we have yet another new agent that is simultaneously

  • up on a down day on big volume

ATHN
127.50-4.19(-3.18%)Oct 1 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.